<DOC>
	<DOCNO>NCT01321554</DOCNO>
	<brief_summary>This multicenter , randomize , double-blind , placebo-controlled Phase 3 study compare progression free survival participant 131 I -refractory DTC radiographic evidence disease progression within prior 12 month , treat lenvatinib 24 mg continuous daily oral dose versus placebo . The study conduct 3 phase : Prerandomization Phase ( screen baseline period ) , Randomization Phase ( double-blind treatment period ) , Extension Phase ( Optional Open Label ( OOL ) Lenvatinib Treatment Period follow-up period ) .</brief_summary>
	<brief_title>A Multicenter , Randomized , Double-Blind , Placebo-Controlled , Phase 3 Trial Lenvatinib ( E7080 ) 131I-Refractory Differentiated Thyroid Cancer ( DTC )</brief_title>
	<detailed_description>Randomization Phase : Participants receive blind study drug ( lenvatinib/placebo ) 2:1 ratio documentation disease progression ( confirmed independent image review ) , development unacceptable toxicity , withdrawal consent . After complete primary analysis , subject treat lenvatinib experienced disease progression may request continue open label lenvatinib dose , accord clinical judgment investigator . Participants discontinue treatment reason disease progression follow Randomization Phase disease progression start another anticancer treatment ; participant enter Extension Phase survival follow-up . Extension Phase : Participants placebo arm disease progression confirm IIR could request enter OOL Lenvatinib Treatment Period receive lenvatinib treatment . Participants receive lenvatinib treatment disease progression ( investigator 's assessment ) , development intolerable toxicity , withdrawal consent . Participants disease progression Randomization Phase enter OOL Lenvatinib Treatment Period participant discontinue lenvatinib treatment OOL Lenvatinib Treatment Period enter follow-up period . Participants follow survival , anticancer treatment record time death .</detailed_description>
	<mesh_term>Thyroid Diseases</mesh_term>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<mesh_term>Lenvatinib</mesh_term>
	<criteria>Inclusion criterion : 1 . Histologically cytologically confirm diagnosis one follow DTC subtypes : Papillary thyroid cancer ( PTC ) follicular thyroid cancer ( FTC ) . 2 . Measurable disease accord ( RECIST 1.1 ) confirm central radiographic review . 3 . 131 Irefractory/resistant disease . 4 . Evidence disease progression within 12 month prior sign inform consent ( +1 month screen window ) . 5 . Prior treatment 0 1 vascular endothelial growthfactor ( VEGF ) vascular endothelial growthfactor receptor ( VEGFR ) target therapy . 6 . Adequate renal , liver , bone marrow , blood coagulation function , define protocol . Exclusion criterion : 1 . Anaplastic medullary carcinoma thyroid 2 . 2 prior VEGF/ VEGFRtargeted therapies 3 . Received anticancer treatment within 21 day investigational agent within 30 day prior first dose study drug . Inclusion criterion OOL Lenvatinib Treatment Period : Participants eligible lenvatinib treatment OOL Lenvatinib Treatment Period meet follow criterion : 1 . Placebotreated participant Randomization Phase progressive disease ( PD ) confirm IIR , request treatment lenvatinib . 2 . Participants continue satisfy specify inclusion exclusion criterion present study protocol . 3 . Participants maximum interval day confirmation PD IIR Cycle 1/Day 1 OOL Lenvatinib Treatment Period less equal 3 month . 4 . No systemic anticancer treatment interval day confirmation PD IIR Cycle 1/Day 1 OOL Lenvatinib Treatment Period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>